Related Experiment Video
Updated: Jul 4, 2026

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
Published on: May 31, 2018
Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function
Sarah N Campion1, Rachel Johnson, Lauren M Aleksunes
1Dept. of Pharmaceutical Sciences, Univ. of Connecticut, 69 North Eagleville Rd., Unit 3092, Storrs, CT 06269-3092, USA.
Abstract:
During acetaminophen (APAP) hepatotoxicity, increased expression of multidrug resistance-associated proteins 2, 3, and 4 (Mrp2-4) occurs. Mrp4 is the most significantly upregulated transporter in mouse liver following APAP treatment. Although the expression profiles of liver transporters following APAP hepatotoxicity are well characterized, the regulatory mechanisms contributing to these changes remain unknown. We hypothesized that Kupffer cell-derived mediators participate in the regulation of hepatic transporters during APAP toxicity. To investigate this, C57BL/6J mice were pretreated with clodronate liposomes (0.1 ml iv) to deplete Kupffer cells and then challenged with APAP (500 mg/kg ip). Liver injury was assessed by plasma alanine aminotransferase and hepatic transporter protein expression was determined by Western blot and immunohistochemistry. Depletion of Kupffer cells by liposomal clodronate increased susceptibility to APAP hepatotoxicity. Although increased expression of several efflux transporters was observed after APAP exposure, only Mrp4 was found to be differentially regulated following Kupffer cell depletion. At 48 and 72 h after APAP dosing, Mrp4 levels were increased by 10- and 33-fold, respectively, in mice receiving empty liposomes. Immunohistochemistry revealed Mrp4 staining confined to centrilobular hepatocytes. Remarkably, Kupffer cell depletion completely prevented Mrp4 induction by APAP. Elevated plasma levels of TNF-alpha and IL-1beta were also prevented by Kupffer cell depletion. These findings show that Kupffer cells protect the liver from APAP toxicity and that Kupffer cell mediators released in response to APAP are likely responsible for the induction of Mrp4.
Insights
Kupffer cells protect the liver from acetaminophen (APAP) toxicity by regulating Mrp4 transporter expression. Depleting Kupffer cells exacerbates APAP liver injury and prevents Mrp4 induction.
Area of Science:
- Hepatology
- Immunology
- Toxicology
Background:
- Acetaminophen (APAP) overdose causes liver injury, associated with increased expression of multidrug resistance-associated proteins (Mrps).
- The regulatory mechanisms behind altered hepatic transporter expression during APAP hepatotoxicity are not fully understood.
- Kupffer cells, the resident liver macrophages, are implicated in inflammatory responses to APAP.
Purpose of the Study:
- To investigate the role of Kupffer cells in regulating hepatic transporter expression during APAP-induced liver injury.
- To determine if Kupffer cell-derived mediators influence the induction of Mrp4 transporter following APAP exposure.
Main Methods:
- C57BL/6J mice were depleted of Kupffer cells using clodronate liposomes.
- Mice were subsequently challenged with acetaminophen (APAP) to induce hepatotoxicity.
- Liver injury was assessed via plasma alanine aminotransferase levels; hepatic transporter protein expression (Mrp4) was analyzed using Western blot and immunohistochemistry.
Main Results:
- Kupffer cell depletion increased susceptibility to APAP hepatotoxicity.
- APAP treatment significantly upregulated Mrp4 transporter expression in control mice (10-33 fold at 48-72h).
- Kupffer cell depletion completely prevented the APAP-induced upregulation of Mrp4 and reduced elevated TNF-alpha and IL-1beta plasma levels.
Conclusions:
- Kupffer cells play a protective role in acetaminophen-induced liver injury.
- Mediators released by Kupffer cells in response to APAP are crucial for the induction of the Mrp4 transporter.
- Targeting Kupffer cell-mediated pathways may offer therapeutic strategies for APAP hepatotoxicity.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Pharmacokinetics in Pediatric Patients: Drug Metabolism
